Profile data is unavailable for this security.
About the company
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It provides diagnostic information services for infectious diseases, such as tuberculosis (e.g., T.SPOT.TB and Quantiferon offerings) and tick-borne disease (e.g., Accutix offering). Its comprehensive offerings in drug monitoring and toxicology, in neurology diagnostics, in advanced cardiovascular diagnostic information services (e.g. CARDIO IQ and Cleveland HeartLab offerings through its Cardiometabolic Center of Excellence), and in cancer diagnostics. Its Diagnostic Solutions business consists of its risk assessment services and healthcare information technology businesses. Its risk assessment service, ExamOne, is a provider of risk assessment services for the life insurance industry in North America.
- Revenue in USD (TTM)9.29bn
- Net income in USD842.00m
- Incorporated1996
- Employees40.00k
- LocationQuest Diagnostics Inc500 Plaza DriveSECAUCUS 07094United StatesUSA
- Phone+1 (973) 520-2700
- Fax+1 (302) 655-5049
- Websitehttps://www.questdiagnostics.com/
Mergers & acquisitions
| Acquired company | DGX:NYQ since announced | Transaction value |
|---|---|---|
| Lenco Diagnostic Laboratories Inc | 9.04% | 111.00m |
| Steward Health Care System LLC-Outreach Laboratory Services Business Select Assets | -1.37% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemed Corp | 2.29bn | 283.41m | 8.45bn | 15.09k | 30.04 | 7.11 | 24.47 | 3.68 | 18.58 | 18.58 | 150.33 | 78.46 | 1.45 | 138.48 | 13.85 | 152,017.80 | 17.94 | 19.53 | 21.86 | 24.64 | 35.47 | 34.60 | 12.36 | 12.60 | 1.88 | -- | 0.0114 | 8.15 | 6.06 | 4.90 | 9.17 | 5.80 | 1.46 | 6.10 |
| Encompass Health Corp | 4.96bn | 386.50m | 8.59bn | 22.36k | 22.45 | 4.93 | 11.00 | 1.73 | 3.80 | 3.68 | 48.76 | 17.30 | 0.8276 | -- | 8.74 | 221,721.20 | 8.36 | 6.37 | 10.58 | 7.94 | 95.50 | 95.58 | 10.10 | 9.16 | -- | 5.59 | 0.5298 | 30.78 | 10.41 | 2.34 | 41.31 | 4.49 | 16.60 | -10.42 |
| Solventum Corp | 8.20bn | 1.29bn | 10.69bn | 22.01k | 8.27 | 2.78 | 5.79 | 1.30 | 7.48 | 7.48 | 47.54 | 22.30 | -- | -- | -- | 372,699.60 | -- | -- | -- | -- | 57.64 | -- | 15.73 | -- | 1.33 | 43.79 | 0.6832 | -- | 0.8241 | -- | 0.2234 | -- | -- | -- |
| Davita Inc | 12.34bn | 815.64m | 11.82bn | 70.00k | 15.30 | 12.76 | 6.40 | 0.9578 | 8.81 | 8.81 | 133.10 | 10.56 | 0.7224 | 66.04 | 5.30 | 176,257.20 | 6.40 | 5.62 | 8.50 | 7.45 | 32.40 | 30.70 | 8.85 | 8.33 | 1.37 | 5.01 | 0.7759 | -- | 4.57 | 1.26 | 26.44 | 2.33 | -10.47 | -- |
| Universal Health Services, Inc. | 14.66bn | 816.29m | 11.85bn | 73.35k | 15.17 | 1.91 | 8.53 | 0.8086 | 11.79 | 11.79 | 211.29 | 93.48 | 1.06 | -- | 6.77 | 199,837.00 | 5.96 | 6.44 | 6.98 | 7.63 | -- | -- | 5.61 | 6.55 | 1.28 | 6.16 | 0.4352 | 6.06 | 6.59 | 5.80 | 6.32 | -1.47 | 1.17 | 14.87 |
| Tenet Healthcare Corp | 20.90bn | 2.62bn | 12.74bn | 78.14k | 5.04 | 3.69 | 3.03 | 0.6097 | 25.87 | 25.87 | 201.91 | 35.35 | 0.7466 | 9.04 | 6.50 | 267,391.00 | 11.97 | 3.61 | 17.38 | 5.09 | 82.64 | 82.97 | 16.03 | 4.95 | 1.37 | 4.49 | 0.6267 | 0.00 | 7.17 | 2.33 | 49.02 | 41.42 | 4.01 | -- |
| Quest Diagnostics Inc | 9.29bn | 842.00m | 15.76bn | 40.00k | 19.09 | 2.45 | 11.96 | 1.70 | 7.43 | 7.43 | 82.00 | 57.95 | 0.6944 | 33.57 | 7.21 | 232,175.00 | 6.51 | 9.28 | 7.61 | 10.81 | 32.95 | 36.64 | 9.37 | 12.97 | 0.8908 | 8.40 | 0.4184 | 25.07 | -6.38 | 4.20 | -9.77 | 3.40 | 1.27 | 7.43 |
| Laboratory Corporation of Amerc Holdings | 12.30bn | 399.20m | 16.96bn | 67.00k | 44.05 | 2.13 | 17.55 | 1.38 | 4.57 | 4.95 | 142.45 | 94.42 | 0.6698 | 18.59 | 4.68 | 183,588.10 | 2.18 | 6.27 | 2.68 | 7.37 | 27.74 | 32.33 | 3.25 | 9.51 | 0.7564 | 5.95 | 0.3934 | -- | 2.51 | 1.42 | -62.16 | -16.40 | 3.62 | -- |
| Molina Healthcare Inc | 35.85bn | 1.07bn | 20.24bn | 18.00k | 18.74 | 4.54 | 16.28 | 0.5645 | 18.43 | 18.43 | 617.11 | 76.15 | 2.48 | -- | 12.18 | 1,991,889.00 | 7.42 | 7.62 | 16.79 | 16.80 | 15.74 | 15.99 | 2.99 | 3.04 | -- | 14.69 | 0.3465 | 0.00 | 6.56 | 12.52 | 37.75 | 9.06 | 22.87 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 13.42m | 12.13% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.78m | 6.12% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 5.20m | 4.70% |
| Victory Capital Management, Inc. (Investment Management)as of 31 Mar 2024 | 3.92m | 3.54% |
| American Century Investment Management, Inc.as of 31 Mar 2024 | 3.87m | 3.50% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 2.61m | 2.36% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.53m | 2.29% |
| Davis Selected Advisers LPas of 31 Mar 2024 | 2.38m | 2.15% |
| Grantham, Mayo, Van Otterloo & Co. LLCas of 31 Mar 2024 | 2.04m | 1.85% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 1.98m | 1.79% |
